Skip to main content

Advertisement

SpringerLink
Log in

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Simpson AJ, Caballero OL, Jungbluth A, Chen Y-T, Old LJ . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615–625.

    Article  CAS  Google Scholar 

  2. Liggins AP, Brown PJ, Asker K, Pulford K, Banham AH . A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 2004; 91: 141–149.

    Article  CAS  Google Scholar 

  3. Guinn B-A, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293–1304.

    Article  CAS  Google Scholar 

  4. Xie X, Wacker HH, Huang S, Regitz E, Preuss K-D, Romeike B et al. Differential expression of cancer testis genes in histological subtypes of non-Hodgkin’s lymphomas. Clin Cancer Res 2003; 9: 167–173.

    CAS  PubMed  Google Scholar 

  5. Kalejs M, Erenpreisa J . Review Cancer/testis antigens and gametogenesis: a review and ‘brain-storming’ session. Cancer Cell Int 2005; 5: 1–11.

    Article  Google Scholar 

  6. Jungbluth AA, Chen Y-T, Stockert E, Busam KJ, Kolb D, Iversen K et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 856–860.

    Article  CAS  Google Scholar 

  7. Sahota S, Goonewardena M, Cooper C, Liggins AP, Ait-Tahar K, Zojer N et al. PASD1 is a potential multiple myeloma associated antigen. Blood (in press).

  8. Vose J . Personalised immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Clin Adv Hematol Oncol 2006; 3: 923–932.

    Google Scholar 

Download references

Acknowledgements

This work is supported by grants from the Leukemia Research Fund (APL, KA-T, AHB, KP), Isis University Innovation Fund and the Julian Starmer-Smith Memorial Fund (CDOC). We are also grateful to the CNIO Tumor Bank Network.

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK

    C D O Cooper, A P Liggins, K Ait-Tahar, A H Banham & K Pulford

  2. Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

    G Roncador

Authors
  1. C D O Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A P Liggins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Ait-Tahar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Roncador
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A H Banham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Pulford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Pulford.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooper, C., Liggins, A., Ait-Tahar, K. et al. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 20, 2172–2174 (2006). https://doi.org/10.1038/sj.leu.2404424

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404424

  • Springer Nature Limited

This article is cited by

Search

Navigation